Print this page
-
Sequential Combined TAS-102 and Oxaliplatin Alternating with TAS-102 and Irinotecan (Sequential TASOXIRI) with Bevacizumab for Late-Line Metastatic Colorectal Cancer.
Protocol: 072303Principal Investigator:
-
Howard Hochster
Applicable Disease Sites: Colon -
A Phase 1/1b Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2
Expression
Protocol: 072305Principal Investigator:
-
Howard Hochster
Applicable Disease Sites: Pancreas -
Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial.
Protocol: 072306Principal Investigator:
-
Brett Ecker
Applicable Disease Sites: Other Digestive Organ -
A Phase II, open-label, multi-cohort, multicenter study in patients with unresectable HEPATOCELLULAR CARCINOMA and CHILDPUGH B7 and B8 Cirrhosis
Protocol: 072309Principal Investigator:
-
Howard Hochster
Applicable Disease Sites: Liver -
A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors.
Protocol: 072310Principal Investigator:
-
Matthew Deek
Applicable Disease Sites: Prostate
Rectum
Small Intestine -
Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere ) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy
Protocol: 072311Principal Investigator:
-
Sharon Li
Applicable Disease Sites: Liver -
Phase 2 Study of Gemcitabine, Cisplatin, Quemliclustat (AB680) and Zimberelimab (AB122) during First-Line Treatment of Advanced Biliary Tract Cancers Big Ten Cancer Research Consortium BTCRC-GI22-564
Protocol: 072401Principal Investigator:
-
Howard Hochster
Applicable Disease Sites: Small Intestine -
A Phase 1/Randomized Phase 2 Study of M3814 (peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
Protocol: 072403Principal Investigator:
-
Matthew Deek
Applicable Disease Sites: Pancreas -
ScreenNJ Resource and Evaluation Unit
Protocol: 131820Applicable Disease Sites: Colon
Lung -
Practices, knowledge and beliefs of colorectal cancer patients and their providers prescription practices regarding anemia and oral iron supplementation
Protocol: 132003Principal Investigator:
-
Carolyn J Heckman
Applicable Disease Sites: Colon
Rectum -
Personalized Oncology Promoting Equity for Black Lives (PROPEL)
Protocol: 132309Principal Investigator:
-
Anita Y Kinney
Applicable Disease Sites: Breast
Colon
Corpus Uteri
Ovary
Pancreas
Prostate -
The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer.
Protocol: 152301Principal Investigator:
-
Salma Jabbour
Applicable Disease Sites: Rectum -
A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Cancers of the Stomach, Breast, Lung and Cervix.
Protocol: 192004Principal Investigator:
-
Christian Hinrichs
Applicable Disease Sites: Any Site
Breast
Cervix
Lung
Stomach -
A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-Associated Cancers
Protocol: 192104Principal Investigator:
-
Christian Hinrichs
Applicable Disease Sites: Breast
Cervix
Lip, Oral Cavity and Pharynx
Other Female Genital
Other Male Genital
Stomach -
A Phase II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers.
Protocol: 192204Principal Investigator:
-
Christian Hinrichs
Applicable Disease Sites: Anus
Cervix
Larynx
Lip, Oral Cavity and Pharynx
Other Female Genital
Other Male Genital
- 1
- 2